TY - JOUR
T1 - Switching the Chemoselectivity in the Preparation of [18F]FNA-N-CooP, a Free Thiol-Containing Peptide for Targeted Positron Emission Tomography Imaging of Fatty Acid Binding Protein 3
AU - Dillemuth, Pyry
AU - Lövdahl, Petter
AU - Karskela, Tuomas
AU - Ayo, Abiodun
AU - Ponkamo, Jesse
AU - Liljenbäck, Heidi
AU - Paunonen, Sami
AU - Kunnas, Jonne
AU - Rajander, Johan
AU - Tynninen, Olli
AU - Rosenholm, Jessica M.
AU - Roivainen, Anne
AU - Laakkonen, Pirjo
AU - Airaksinen, Anu J.
AU - Li, Xiang-Guo
N1 - doi: 10.1021/acs.molpharmaceut.4c00546
Ännu någon länk behövs, se https://pubs.acs.org/page/copyright/journals/posting_policies.html?_gl=1*1buugpc*_ga*ODA2NzQ1MDA2LjE3MjMxODU4NDA.*_ga_3YE6YD0SWD*MTcyMzQ2MTk2MC4yLjAuMTcyMzQ2MTk2MS4wLjAuMA..
PY - 2024/8/5
Y1 - 2024/8/5
N2 - Fatty acid binding protein 3 (FABP3) is expressed both in tumor cells and in the tumor vasculature, making it a potential target for medical imaging and therapy. In this study, we aimed to radiolabel a CooP peptide with a free amino and thiol group, and evaluate the radiolabeled product [18F]FNA-N-CooP for imaging FABP3 expression in breast cancer brain metastases by positron emission tomography. [18F]FNA-N-CooP was prepared by highly chemoselective N-acylation and characterized using different chemical approaches. We validated its binding to the target using in vitro tissue section autoradiography and performed stability tests in vitro and in vivo. [18F]FNA-N-CooP was successfully synthesized in 16.8% decay-corrected radiochemical yield with high radiochemical purity (98.5%). It exhibited heterogeneous binding on brain metastasis tissue sections from a patient with breast cancer, with foci of radioactivity binding corresponding to FABP3 positivity. Furthermore, the tracer binding was reduced by 55% in the presence of nonradioactive FNA-N-CooP a blocker, indicating specific tracer binding and that FABP3 is a viable target for [18F]FNA-N-CooP. Favorably, the tracer did not bind to necrotic tumor tissue. However, [18F]FNA-N-CooP displayed limited stability both in vitro in mouse plasma or human serum and in vivo in mouse, therefore further studies are needed to improve the stability [18F]FNA-N-CooP to be used for in vivo applications.
AB - Fatty acid binding protein 3 (FABP3) is expressed both in tumor cells and in the tumor vasculature, making it a potential target for medical imaging and therapy. In this study, we aimed to radiolabel a CooP peptide with a free amino and thiol group, and evaluate the radiolabeled product [18F]FNA-N-CooP for imaging FABP3 expression in breast cancer brain metastases by positron emission tomography. [18F]FNA-N-CooP was prepared by highly chemoselective N-acylation and characterized using different chemical approaches. We validated its binding to the target using in vitro tissue section autoradiography and performed stability tests in vitro and in vivo. [18F]FNA-N-CooP was successfully synthesized in 16.8% decay-corrected radiochemical yield with high radiochemical purity (98.5%). It exhibited heterogeneous binding on brain metastasis tissue sections from a patient with breast cancer, with foci of radioactivity binding corresponding to FABP3 positivity. Furthermore, the tracer binding was reduced by 55% in the presence of nonradioactive FNA-N-CooP a blocker, indicating specific tracer binding and that FABP3 is a viable target for [18F]FNA-N-CooP. Favorably, the tracer did not bind to necrotic tumor tissue. However, [18F]FNA-N-CooP displayed limited stability both in vitro in mouse plasma or human serum and in vivo in mouse, therefore further studies are needed to improve the stability [18F]FNA-N-CooP to be used for in vivo applications.
UR - https://pubs.acs.org/cms/10.1021/mpohbp.2024.21.issue-8/asset/mpohbp.2024.21.issue-8.xlargecover-2.jpg
U2 - 10.1021/acs.molpharmaceut.4c00546
DO - 10.1021/acs.molpharmaceut.4c00546
M3 - Article
SN - 1543-8384
VL - 21
SP - 4147
EP - 4156
JO - Molecular Pharmaceutics
JF - Molecular Pharmaceutics
IS - 8
ER -